Literature DB >> 9234533

The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs.

W L McClements1, M E Armstrong, R D Keys, M A Liu.   

Abstract

Plasmid expression vectors encoding herpes simplex virus type 2 (HSV-2) glycoproteins B (gB) or D (gD) were constructed and tested for their ability to immunize guinea pigs against genital HSV infection. Immunization with a plasmid expressing the aminoterminal 707 amino acids (aa) of gB induced humoral immune responses detected by ELISA and virus neutralization. When challenged by vaginal infection, immunized animals were partially protected from genital herpes, exhibiting significantly reduced primary and subsequent recurrent disease. When the gB plasmid was combined with a plasmid expressing full-length gD, immunized guinea pigs developed humoral responses to both proteins and were also significantly protected from viral challenge.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234533     DOI: 10.1016/s0264-410x(96)00246-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer.

Authors:  C Trollet; Y Pereira; A Burgain; E Litzler; M Mezrahi; J Seguin; M Manich; M R Popoff; D Scherman; P Bigey
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

2.  Evaluation of a novel, anti-herpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea pig model of genital herpes.

Authors:  R Jennings; T L Smith; F Myhren; J Phillips; M L Sandvold
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig.

Authors:  David I Bernstein; Julie D Earwood; Fernando J Bravo; Gary H Cohen; Roselyn J Eisenberg; Jennifer R Clark; Jeffrey Fairman; Rhonda D Cardin
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

Review 4.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

Review 5.  Prospects and perspectives for development of a vaccine against herpes simplex virus infections.

Authors:  Shane C McAllister; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2014-07-31       Impact factor: 5.217

Review 6.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

7.  Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality.

Authors:  Bobbie Ann Austin; Cassandra M James; Peter Härle; Daniel J J Carr
Journal:  Biol Proced Online       Date:  2006-06-14       Impact factor: 3.244

8.  Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.

Authors:  V Durmanová; M Sapák; J Kosovský; I Rezuchová; M Kúdelová; M Buc; J Rajcáni
Journal:  Folia Microbiol (Praha)       Date:  2008-05-15       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.